Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
37 hedge funds and large institutions have $3.1M invested in Unity Biotechnology in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
1.67% less ownership
Funds ownership: 20.54% → 18.87% (-1.7%)
3% less funds holding
Funds holding: 38 → 37 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less capital invested
Capital invested by funds: $5.09M → $3.1M (-$1.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$43.9K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$31.1K |
| 3 |
Jane Street
New York
|
+$26.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.2K |
| 5 |
Squarepoint
New York
|
+$22.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$117K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$102K |
| 3 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
-$83.9K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$75.7K |
| 5 |
Renaissance Technologies
New York
|
-$20.8K |
UBX Hedge Fund Activity: Q4 2024 in Review
37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2024, worth a combined $3.1M — down 39% from $5.09M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new UBX positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $43.9K. The largest seller was UBS O'Connor, exiting entirely with an estimated $117K sold.
- 37 institutional investors held Unity Biotechnology (UBX) as of Q4 2024, down from 38 in Q3 2024.
- Funds reported $3.1M of Unity Biotechnology stock for Q4 2024, down 39% quarter-over-quarter.
- 6 funds opened new Unity Biotechnology positions in Q4 2024 and 5 closed out, a net change of +1 holder.
- The largest Unity Biotechnology buyer in Q4 2024 was Morgan Stanley, an estimated $43.9K added.
- The largest Unity Biotechnology seller in Q4 2024 was UBS O'Connor, an estimated $117K sold.
Based on aggregated 13F filings for Q4 2024.